Revance to Participate in Upcoming Investor Conferences

May 31, 2016

NEWARK, Calif., May 31, 2016 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will participate in two upcoming investor conferences.

Revance management is scheduled to present at the Jefferies 2016 Global Healthcare Conference in New York, NY on Tuesday, June 7 at 11:30am ET.

Revance management is also scheduled for a fireside chat at the William Blair 36th Annual Growth Stock Conference in Chicago, IL on Tuesday, June 14 at 10:10am CT.

Interested parties can access the live audio webcast for both of these conferences from the Investor Relations section of the company's website at The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.

About Revance Therapeutics, Inc. 
Revance, a Silicon Valley-based biotechnology company, is committed to the advancement of remarkable science.  The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including neurology.  Revance's trajectory to commercial success begins with the company's novel and proprietary TransMTS® carrier-peptide delivery system, which is uniquely designed to target and transport macromolecules to their desired location.

Revance's journey to market starts with the neurotoxin daxibotulinumtoxinA, the company's highly purified botulinum toxin type A.  The TransMTS technology is used in the delivery of botulinum toxin through two novel drug product candidates:  DaxibotulinumtoxinA Topical Gel (RT001) that permits needle-free application, and DaxibotulinumtoxinA for Injection (RT002), which is designed to enable targeted administration and long-lasting effect.

Revance is developing RT001 and RT002 for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles, excessive sweating and muscle movement disorders.  The company holds worldwide rights for all indications of RT001, RT002, and the TransMTS technology platform.   Beyond botulinum toxin, Revance believes the TransMTS technology can be applied to transdermal, mid-dermal or deep tissue delivery of a variety of other macromolecules.  More information on Revance can be found at

"Revance Therapeutics", TransMTS®, "Remarkable Science Changes Everything", and the Revance logo are registered trademarks of Revance Therapeutics, Inc.



Revance TherapeuticsJeanie Herbert

(714) 325-3584

Burns McClellanAmi Bavishi

(212) 213-0006

Trade Media:

Nadine Tosk

(504) 453-8344

Primary Logo

Source: Revance Therapeutics, Inc

News Provided by Acquire Media